Every 8-K that IPG Photonics Corporation (IPGP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IPGP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IPGP filings page.
IPG Photonics Corporation (IPGP) has entered into a definitive Share Purchase Agreement to acquire 100% of Lumibird Medical, a French subsidiary of Lumibird S.A. The agreement follows the seller’s exercise of a previously disclosed put option.
The purchase price is €300 million on a cash-free, debt-free basis, payable in cash at closing and subject to customary adjustments, plus up to €50 million in contingent earn-out consideration tied to 2026 and 2027 performance metrics. IPG Photonics expects to fund the deal with cash on hand. The parties have put in place a warranty and indemnity insurance policy, with the seller providing fundamental representations and limited business warranties. Closing is subject to customary conditions, including French foreign direct investment approval and an AMF waiver, and is expected in the fourth quarter of 2026.
IPG Photonics reported second quarter 2026 revenue of $278.6 million, up 11% year over year, with GAAP gross margin improving to 40.4%. Operating income was $4.5 million, and GAAP net income declined 21% to $5.2 million, or $0.12 per diluted share, partly reflecting impairment charges of $17,574 (in thousands) and a 58% tax rate.
Industrial Solutions revenue grew 16% year over year and represented 85% of total sales, while Advanced Solutions revenue decreased. Emerging growth products contributed 58% of revenue. Adjusted gross margin was 40.7%, adjusted EBITDA rose 54% to $48.5 million, and adjusted EPS increased 93% to $0.58. The company generated $37.8 million of operating cash flow and invested $20.7 million in capital expenditures. For the third quarter of 2026, guidance calls for revenue of $265–$295 million, adjusted gross margin of 37.5%–40.5%, adjusted operating expenses of $92–$95 million, adjusted EPS of $0.30–$0.60, and adjusted EBITDA of $35–$51 million.
IPG Photonics Corporation agreed a Put Option Agreement with Lumibird S.A. for the proposed acquisition of 100% of Lumibird Medical for a cash purchase price of €300 million, on a cash-free, debt-free basis, plus up to €50 million earnout tied to 2026–2027 performance. IPG Photonics plans to fund the deal with cash on hand. After completion of the required French works council consultation and the seller’s exercise of the put, IPG Photonics is irrevocably committed to sign a share purchase agreement, with closing targeted in the fourth quarter of 2026, subject to customary conditions and authorization under the French foreign direct investment regime.
The agreements include exclusivity for IPG Photonics, warranty and indemnity insurance covering many seller warranties, capped seller liability for business warranties, and three-year non-compete and non-solicitation provisions on the seller. Lumibird Medical generated 2025 revenue of €112.2 million and EBITDA of €24.1 million, and IPG Photonics describes the business as high-margin and expects the acquisition to be accretive to gross margin, EBITDA and adjusted EPS while adding approximately $1 billion to the Advanced Solutions addressable market. A supplemental investor presentation indicates the €300 million price equals 15.9x 2025 adjusted EBITDA of €18.9 million and that the combined medical businesses would have about $204 million of 2025 sales.
IPG Photonics Corporation reported the results of its annual meeting of stockholders held on May 12, 2026. Stockholders elected ten directors, with each nominee receiving over 36 million votes in favor and sizable broker non-votes recorded for each seat.
Stockholders approved the advisory vote on executive compensation, with 27,089,325 votes for and 10,719,258 against, along with 159,740 abstentions and 2,089,675 broker non-votes. They also ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026, with 39,419,373 votes for, 614,181 against and 24,444 abstentions.
IPG Photonics reported first-quarter 2026 revenue of $265.5 million, up 17% from a year earlier, led by 21% growth in Industrial Solutions. Despite higher sales, GAAP operating results swung to a loss of $7.7 million, and net income declined to $1.6 million or $0.04 per diluted share.
Non-GAAP performance was stronger: adjusted EBITDA reached $35.2 million and adjusted earnings per diluted share were $0.29. The company highlighted cost management efforts and noted tariffs and higher product costs pressured margins. Emerging growth products contributed 53% of revenue, with notable gains in welding, cutting, marking, and cleaning applications.
For the second quarter of 2026, IPG Photonics guides to revenue of $260–$290 million, adjusted gross margin of 37–40%, adjusted operating expenses of $92–$95 million, adjusted EPS of $0.25–$0.55, and adjusted EBITDA of $32–$48 million. The company also entered an agreement with TRUMPF Laser- und Systemtechnik SE to resolve and dismiss all patent litigation worldwide between the parties.
IPG Photonics Corporation reported that the Unified Patent Court’s local division in Düsseldorf ruled that certain uses and designs of its adjustable mode beam (AMB) lasers infringe European Patent 2,624,031 held by Trumpf SE & Co. KG. The decision currently affects AMB laser products sold in Germany, France and Italy and relates to less than 1% of IPG’s total sales. IPG is putting contingency measures in place to support AMB customers, while other IPG laser models were not involved and the broader product portfolio remains available. Remedies for the patent owner, such as an injunction, product recall and damages, may be enforced and determined later once required conditions are met. IPG disagrees with the decision and plans to appeal to the UPC Court of Appeal and pursue additional available measures.
IPG Photonics Corporation reported that the Local Division of the Unified Patent Court in Mannheim, Germany ruled that certain designs of its adjustable mode beam (AMB) lasers used in welding and cutting applications infringe European Patent 2,951,625 held by Trumpf SE & Co. KG.
The decision affects specific AMB laser products sold in seven UPC member states, including Germany, France and Italy, and the company states these products represent less than 1% of its total sales. Remedies for the patent owner, such as an injunction, recall and damages, will be determined later after required conditions are met. IPG is implementing contingency measures to support AMB customers, notes that its other lasers were not involved, and plans to appeal the ruling to the UPC Court of Appeal.
IPG Photonics Corporation reported stronger fourth quarter and full-year 2025 results, while authorizing a new share repurchase program of up to $100 million. Fourth quarter revenue reached $274.5 million, up 17% year over year, with net income rising to $13.3 million or $0.31 per diluted share, compared with $7.8 million or $0.18 per diluted share a year earlier. GAAP gross margin declined to 36.1% from 38.6% due to higher product costs and tariffs, while adjusted EBITDA grew to $41.2 million and adjusted earnings per diluted share increased to $0.46.
For full-year 2025, revenue was $1,003.8 million, up 3% from 2024, and net income was $31.1 million after a prior-year net loss of $181.5 million that included significant divestiture and impairment charges. Cash and cash equivalents were $403.8 million at year-end, with an additional $512.1 million in short- and long-term investments. For the first quarter of 2026, the company expects revenue between $235 million and $265 million, adjusted gross margin between 37% and 39%, operating expenses of $90 million to $92 million, adjusted earnings per diluted share of $0.10 to $0.40, and adjusted EBITDA of $25 million to $40 million.
IPG Photonics Corporation filed a current report to let investors know it has released financial results for the quarter ended September 30, 2025. The company reported these quarterly results through a press release dated November 4, 2025, which is furnished as Exhibit 99.1.
The company notes that this earnings press release, provided under Item 2.02, is being furnished rather than filed, meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities filings unless specifically referenced.
IPG Photonics amended and restated its Executive Severance Plan, replacing the prior plan and extending coverage generally to executives at the Vice President level and above (the CEO is not a participant). The updated plan clarifies severance triggers for an Involuntary Termination and adjusts treatment of performance-based equity and cash bonuses depending on whether a termination follows a Change in Control. Key changes include prorating performance equity for Tier One executives based on actual performance with an extra twelve months of deemed service, lump-sum cash bonus multiples of 200% for Tier One and 150%/100% for Tier Two/Three in Change in Control scenarios, and a temporary two-year transition window that preserves enhanced benefits for Tier Two and Tier Three executives for qualifying terminations within 24 months of a Change in Control. Four SVPs will be covered as Tier One and had prior employment agreements terminated, continuing as at-will employees under participation agreements that include general releases.